Announcement on Company Obtaining Australian Drug GMP Compliance Certificate

Tonghe Pharmaceutical Co., Ltd.·August 4, 2026·1 page

✨ AI Summary

Jiangxi Tonghe Pharmaceutical Co., Ltd. has received GMP compliance certificates from the Australian TGA for its Mirabegron and Empagliflozin APIs. This certification signifies TGA's recognition of the company's quality systems and production facilities, facilitating international market expansion. The approval grants market access in Australia, expected to boost international sales. Investors are advised to exercise caution due to industry-specific risks.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Jiangxi Tonghe Pharmaceutical Co., Ltd.

Announcement on Company Obtaining Australian Drug GMP Compliance Certificate

The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.

Jiangxi Tonghe Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") recently received GMP compliance certificates for Mirabegron and Empagliflozin APIs from the Australian Therapeutic Goods Administration (TGA). The relevant information is as follows:

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.